ReviewDepression and Alzheimer's disease: Neurobiological links and common pharmacological targets
Introduction
Depression is one of the most prevalent and life-threatening forms of mental illnesses and a major cause of morbidity worldwide. Estimates of prevalence range from 5 to 20% of the general population, when people with mild depressive episodes are included (Fava and Kendler, 2000, Kessler et al., 2005). Depression is associated with significant disability (Murray and Lopez, 1997) and with excess mortality (Cuijpers and Smit, 2002) particularly from cardiovascular disease (Rivelli and Jiang, 2007).
Current antidepressant drugs, which are directed against monoaminergic systems, provide a useful therapeutic tool, but approximately 30% of depressed patients failed to respond to these drugs and antidepressants produce remission only in 30% of patients. This can be explained by the fact that the pathophysiology of depression has not been completely elucidated, and treatments have been developed following the “monoaminergic hypothesis” of depression without taking into account other mechanisms involved in the pathophysiology of the disorder. The identification of these mechanisms represents a fundamental step for the identification of new targets and the design of new antidepressant drugs. Recent studies suggest that factors other than monoamine deficiency or imbalances between various neurotransmitter systems must be considered when describing the neurobiological basis of major depression, such as alterations in mechanisms to resilience to stress, reduced synaptic plasticity, impaired adult hippocampal neurogenesis and neurodegenerative phenomena in the hippocampus (Krishnan and Nestler, 2008).
Neurodegeneration is also the main histopathological feature of Alzheimer's disease, a devastating disorder affecting more than 37 million people worldwide. It is mainly characterized by memory loss, with disoriented behaviour and impairments in language, comprehension, and spatial skills. Neuropsychiatric symptoms, such as depression, psychosis and agitation are also frequent in people with Alzheimer's disease, and are a common precipitant of institutional care (Ballard et al., 2008). Current drugs for Alzheimer's disease are only symptomatic, but do not interfere with the underlying pathogenic mechanisms of the disease (Klafki et al., 2006). Therefore, recent efforts in Alzheimer's disease research are now directed to the identification of new molecular targets for the development of disease-modifying drugs able to counteract the degenerative processes and the resulting memory loss in Alzheimer's disease patients.
Alzheimer's disease is characterized by the presence of ß-amyloid in the senile plaques, intracellular aggregates of tau protein in the neurofibrillary tangles, and progressive neuronal loss (Hardy and Selkoe, 2002). Genetic studies and evidence from animal models support a primary role for ß-amyloid in the cascade of events which leads to neuronal death in Alzheimer's disease brain (Hardy and Selkoe, 2002). Oligomeric species composed of aggregated ß-amyloid are believed to exert toxic effects on synaptic and cellular functions, finally leading to neurodegeneration (Cerpa et al., 2008). Different mechanisms have been proposed to explain ß-amyloid neurotoxicity, such as oxidative stress (Butterfield et al., 2007), amplification of N-methyl-d-aspartate (NMDA) toxicity (Hynd et al., 2004), cell cycle activation in differentiated neurons (Giovanni et al., 1999, Copani et al., 1999, Herrup et al., 2004, Copani et al., 2007), and finally the sustained loss of the canonical Wnt pathway, a signalling pathway essential for maintaining neuronal homeostasis (Caricasole et al., 2004, Inestrosa et al., 2007).
Recent evidence, from epidemiology to neurobiology, suggests a strong relationship between depression and dementia. For different years depression and dementia have been considered completely distinct clinical entities. The term “pseudodementia” is used to define a clinical picture characterized by depression associated with cognitive impairment and responsiveness to antidepressant treatment, as opposed to depression as an early symptom of dementia, which is instead unresponsive to antidepressants (Gualtieri and Johnson, 2008). Recent evidence suggests that depression can act as a risk factor for dementia, in particular Alzheimer's disease, and, most importantly, common pathophysiological mechanisms between these two diseases have been identified, which might explain the progression from depression to Alzheimer's disease (Fig. 1). In the present review we will examine this evidence, focusing on the common molecular pathways as new pharmacological targets for the treatment of both depression and Alzheimer's disease.
Section snippets
The connection between depression and dementia: epidemiological evidence
Different studies suggest that depressive disorder is associated with increased risk of developing cognitive dysfunction (Kessing, 1998, Castaneda et al., 2008) and eventually dementia, in particular Alzheimer's disease (Geerlings et al., 2000, Ownby et al., 2006). Several groups have examined the temporal relationship between depression and Alzheimer's disease to understand whether depression is simply a prodromal symptom of Alzheimer's disease which precedes the onset of cognitive deficits,
Stress and dysfunction of the hypothalamic–pituitary–adrenal axis
Epidemiological evidence supports a role for stress as a risk factor both for depression (Pittenger and Duman, 2008) and Alzheimer's disease (Bao et al., 2008, Simard et al., 2009). Several studies clearly show that chronic exposure to stress and stressful life events may lead to the development of major depression (Czéh and Lucassen, 2007, Kendler et al., 1999, van Praag, 2004, Charney and Manji, 2004, Pariante, 2003), and that elderly individuals prone to psychological distress are more
Conclusion
In the present review we have examined recent evidence on the common molecular mechanisms and cascades between depression and Alzheimer's disease. The above short review did not intend to cover the vast amount of data in this field.
According to the discussed data we suggest that hyperactivation of HPA axis, chronic inflammation and deficit of neurotrophin signaling can be considered as common pathophysiological mechanisms between depression and Alzheimer's disease (Fig. 1) and are potential new
References (146)
- et al.
+ 10 T/C polymorphisms in the gene of transforming growth factor-beta1 are associated with neurodegeneration and its clinical evolution
Mech. Ageing Dev.
(2007) - et al.
The stress system in depression and neurodegeneration: focus on the human hypothalamus
Brain Res. Rev.
(2008) - et al.
Corticosteroids and cognition
J. Psychiatr. Res.
(2001) - et al.
An open label trial of C-1073 (mifepristone) for psychotic major depression
Biol. Psychiatry
(2002) - et al.
A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction
Contemp. Clin. Trials
(2009) - et al.
Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression
Neurobiol. Aging
(2009) - et al.
Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment
Free Radic. Biol. Med.
(2007) - et al.
TGF-beta 1 protects against Abeta-neurotoxicity via the phosphatidylinositol-3-kinase pathway
Neurobiol. Dis.
(2008) - et al.
A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults
J. Affect. Disord.
(2008) - et al.
Suppression of cortisol following dexamethasone in demented patients
Psychol. Res.
(1986)
The nature of the cell cycle in neurons: focus on a “non-canonical” pathway of DNA replication causally related to death
Biochim. Biophys. Acta
Excess mortality in depression: a meta-analysis of community studies
J. Affect. Disord.
Glucocorticoids may initiate Alzheimer's disease: a potential therapeutic role for mifepristone (RU-486)
Med. Hypotheses
Depression: a case of neuronal life and death?
Biol. Psychiatry
A neurotrophic model for stress-related mood disorders
Biol. Psychiatry
The BDNF Val66Met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function
Cell
Neuropsychological deficits among patients with late-onset minor and major depression
Arch. Clin. Neuropsychol.
Major depressive disorder
Neuron
Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy
J. Affect. Disord.
Involvement of cell cycle elements, cyclin-dependent kinases, pRb, and E2F-DP, in -amyloid-induced neuronal death
J. Biol. Chem.
Age-related cognitive decline in patients with mood disorders
Prog. Neuropsychopharmacol. Biol. Psychiatry
HPA axis responsivity to dexamethasone and cognitive impairment in dementia
Prog. Neuropsychopharmacol. Biol. Psychiatry
IL-2 and IL-6 secretion in dementia: correlation with type and severity of disease
J. Neurol. Sci.
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease
Neurochem. Int.
Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs
Brain Res. Mol. Brain Res.
Antidepressants and dementia
J. Affect. Disord.
The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive Disorder
Int. Immunopharmacol.
Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: comparison of stressors
Neuroscience
Antidepressant action: to the nucleus and beyond
Trends Pharmacol. Sci.
The effects of chronic stress on hippocampal morphology and function: an evaluation of chronic restraint paradigms
Brain Res.
Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease
Exp. Gerontol.
Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease
Prog. Neurobiol.
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Lancet
Cytokine-serotonin interactions through indoleamine 2, 3 dioxygenase: a neurodegenerative hypothesis of depression
Med. Hypotheses
Th1, Th2, and Th3 cytokine alterations in major depression
J. Affect. Disord.
Chronic corticosterone administration dose dependently modulates Abeta(1–42) and NMDA-induced neurodegeneration in rat magnocellular nucleus basalis
J. Neuroendocrinol.
Inflammatory aspects of depression
Inflamm. Allergy Drug Targets
The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice
Proc. Natl. Acad. Sci. U. S. A.
A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study
Neurology
BDNF in schizophrenia, depression and corresponding animal models
Mol. Psychiatry
Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression
J. Neural Transm.
Neuropsychiatric symptoms in the dementias
Curr. Opin. Neurol.
Prognosis of late life depression: a three-year cohort study of outcome and potential predictors
Int. J Geriatr. Psychiatry
Neuropsychiatric symptoms in dementia: importance and treatment considerations
Int. Rev. Psychiatry
Hippocampal morphology and distinguishing late-onset from early-onset elderly depression
Am. J. Psychiatry
Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro
Endocrinology
Rapid reversal of psychotic depression using mifepristone
J. Clin. Psychopharmacol.
Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress
Science
Anti-inflammatory drugs protect against Alzheimer disease at low doses
Arch. Neurol.
Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression
Int. Clin. Psychopharmacol.
Cited by (252)
Depression as a risk factor for dementia: Pathophysiology and preclinical study models
2024, Psiquiatria BiologicaSex steroids and the female brain across the lifespan: insights into risk of depression and Alzheimer's disease
2023, The Lancet Diabetes and EndocrinologyForgetful, sad and old: Do vascular cognitive impairment and depression share a common pre-disease network and how is it impacted by ageing?
2022, Journal of Psychiatric ResearchPathophysiology of Alzheimer's Disease
2022, Psychiatric Clinics of North America